Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 18Carboplatin 16Cisplatin 14Paclitaxel 9Gemcitabine 7pembrolizumab 6Crizotinib 5osimertinib 4amivantamab 4Nivolumab 4Docetaxel 4lazertinib 3Vinorelbine 3Ipilimumab 3Afatinib 3selpercatinib 2lorlatinib 2durvalumab 2cemiplimab 2atezolizumab 2alectinib 2Gefitinib 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zenocutuzumab 1trastuzumab deruxtecan 1trametinib 1tepotinib 1telisotuzumab vedotin 1taletrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Non-Small-Cell Lung × telisotuzumab vedotin × Clear all
NCT03539536 2025-11-05

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

AbbVie

Phase 2 Active not recruiting
270 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡